JWT Poised to Win Boehringer, Lilly Drug Pitch

NEW YORK J. Walter Thompson is expected to land international creative duties for a new urinary incontinence drug that will be co-marketed by Boehringer Ingelheim and Eli Lilly & Co., sources said. Estimated billings are $25 million.

The client selected WPP’s JWT, whose London and New York offices pitched the business, after a review involving three other shops: Omnicom’s BBDO in Dusseldorf, Germany; Interpublic’s Foote, Cone & Belding in New York; and Havas’ Euro RSCG Life in London, said sources.

Agency presentations took place last month at Boehringer Ingelheim’s headquarters in Ingelheim, Germany [Adweek, Sept. 29]. JWT, whose London office will likely manage the account, referred calls to the client, who could not be reached.

The drug will target women and hit the market next year.